Brief: Illumina Secures CMS Reimbursement For TruSight Oncology Comprehensive, Expanding Access To Precision Oncology
20/01/2026 14:18
Jan 20 (Reuters) - Illumina Inc ILMN.O: ILLUMINA SECURES CMS REIMBURSEMENT FOR TRUSIGHT™ ONCOLOGY COMPREHENSIVE, EXPANDING ACCESS TO PRECISION ONCOLOGY ILLUMINA INC - FDA-APPROVED TEST REIMBURSED AT $2,989.55 PER TEST Source text: ID:nPn92JJYFa Further company coverage: ILMN.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Illumina
See all newsBrief: Illumina Bioinsight Platform Expands With New Software To Accelerate The Path From Sequencing To Discovery
US RESEARCH ROUNDUP-Analog Devices, IBM, Qualcomm
Brief: Illumina - Establishes Unsecured Commercial Paper Program On October 8, 2026
Brief: Illumina To Announce Third Quarter 2026 Financial Results
Brief: Illumina Releases Spliceai2 To Help Advance Rare Disease Research